INTRODUCTION: Atherosclerosis (AS), characterized by chronic inflammation within the vasculature, is linked to endothelial dysfunction and oxidative stress. The senescence of vascular endothelial cells (VECs) serves as a pathological basis for AS. Stahlianthus involucratus (King ex Baker) Craib ex Loes is a folk medicinal plant commonly used in Guangxi has its rhizome as the active component. In traditional Chinese medicine, it is believed to promote blood circulation, remove blood stasis, stop bleeding, and disperse accumulated blood. Essential oil extracted from Stahlianthus involucratus rhizomes (EOSIR) is a key bioactive component. However, little research has been reported on the effects of EOSIR on cardiovascular disease. METHODS: Validation techniques, including H&E staining and western blotting, were employed to assess the efficacy of EOSIR in both in vivo and in vitro models of AS. RESULTS: In vivo experiments, EOSIR decreased plaque volume in atherosclerotic vessels of mice. Activation of the Nrf2 signaling pathway by EOSIR alleviated ox-LDL-induced injury in HUVECs, including a reduction in cellular senescence, apoptosis, ROS, and mitochondrial membrane potential, effects that were reversed by Nrf2 silencing. EOSIR also restored mitochondrial morphology in cells and enhanced Nrf2 expression as well as ATP levels in aortic tissue. Both in vivo and in vitro, EOSIR upregulated the Nrf2, NQO1, and HO-1 expression, downregulated Keap1 expression, and improved the mitochondrial-associated protein expression. DISCUSSION: These findings suggest that EOSIR may prevent the onset of AS both in vivo and in vitro by modulating the mitochondrial quality control system through the Nrf2 signaling pathway.
The essential oil from the rhizomes of Stahlianthus involucratus attenuates the progression of vascular aging and atherosclerosis by regulating Nrf2-mediated mitochondrial quality.
从 Stahlianthus involucratus 的根茎中提取的精油通过调节 Nrf2 介导的线粒体质量来减缓血管老化和动脉粥样硬化的进程
阅读:7
作者:Li Jianmei, Wang Zaishang, Wang Yu, Lin Jiaxin, Tang Ning, Zheng Chu, Xu Qin
| 期刊: | Frontiers in Pharmacology | 影响因子: | 4.800 |
| 时间: | 2025 | 起止号: | 2025 May 20; 16:1579333 |
| doi: | 10.3389/fphar.2025.1579333 | 研究方向: | 神经科学 |
| 疾病类型: | 动脉粥样硬化 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
